Kinetics and Ecology of Human Papillomavirus Genital Infections in Young Women

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

TERMINATED

Clinical Phase

NA

Total Enrollment

190 participants

Study Classification

INTERVENTIONAL

Study Start Date

2016-11-11

Study Completion Date

2020-09-29

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Most genital infections by human papillomaviruses (HPV) are asymptomatic or benign and clear within a few months or years. There infections are much less studies than chronic infections, even though they represent the main reservoir for the virus. The goal of this project is to decipher the kinetics of the virus and of the host immune response in acute HPV genital infections in your women. This will be performed by following women longitudinally and regularly in order to measure variations in virus load, immune cell count, cytokine concentration and antibody titers. The investigators will also investigate the interaction between these kinetics and host genetics and host vaginal microbiota

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Human Papillomavirus and Rate of Pregnancy Achieved Via Medically Assisted Procreation

NCT01894425

Infertility Sub-fertility Papillomavirus Infections

COMPLETED

Epidemiology of Papillomavirus Infection (HPV) on Infected Women by Human Immunodeficience Virus (HIV) in West Indies and French Guiana.

NCT01226368

1- Women 2- HIV Infection 3- Followed in West Indies and French Guiana for His Infection +1 more

COMPLETED

Agreement Between Oral and Cervical Human Papillomavirus Infection in a French Cohort

NCT02774538

Human Papillomavirus-Related Cervical Carcinoma

COMPLETED NA

Prevalence of HPV Transmission During Medically Assisted Procreation Procedures

NCT02524223

Human Papillomavirus (HPV) Medically Assisted Procreation (MAP) Infertility

COMPLETED NA

Gynaecological Follow-up of a Subset of HPV-015 (NCT00294047) Study Subjects

NCT01190176

Infections, Papillomavirus

COMPLETED PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HPV Genital Infection (Primary Condition Studied) Bacterial Vaginosis Chlamydiae Infection

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Vaginal and blood sampling

Group Type EXPERIMENTAL

vaginal sampling

Intervention Type OTHER

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

vaginal sampling

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Sexually active with at least one new partner over the last 12 months
* Subjects must be able and willing to give written informed consent
* Living in the 'agglomération de Montpellier'

Exclusion Criteria

* History of cervical pathology
* Pregnant or intending to become pregnant soon (in the coming year)
* Infected by HIV
* Undergoing (or planning to undergo) heavy treatment (biotherapy, chemotherapy, immunosuppression)
* Participation in a clinical trial involving administration of drugswithin the last 4 weeks before the screening date

Minimum Eligible Age

18 Years

Maximum Eligible Age

25 Years

Eligible Sex

FEMALE

Accepts Healthy Volunteers

Yes